| Outcome Measures: |
Primary: change in 24-hour weighted mean blood glucose, Day -1 (baseline) to Day 28 | Secondary: change in 24 hour weighted mean blood glucose, Day -1 (baseline) to Day 14|change in blood fasting plasma glucose level, Day -1 (baseline) to Days 7, 14, 21, 28|change in blood plasma glucose level, Change in the parameter at Day 14 or 28 from Day -1, Day -1 (baseline) to Days 14 and 28|change in blood insulin level, Change in the parameter at Day 14 or 28 from Day -1, Day -1 (baseline) to Days 14 and 28|change in blood C-peptide level, Change in the parameter at Day 14 or 28 from Day -1, Day -1 (baseline) to Days 14 and 28|change in blood active GLP-1 level, Change in the parameter at Day 14 or 28 from Day -1, Day -1 (baseline) to Days 14 and 28|change in blood PYY level, Change in the parameter at Day 14 or 28 from Day -1, Day -1 (baseline) to Days 14 and 28|change in blood HbA1c level, Change in the parameter at Day 14 or 28 from Day -1, Day -1 (baseline) to Days 14 and 28|change in blood glycoalbumin level, Change in the parameter at Day 14 or 28 from Day -1, Day -1 (baseline) to Days 14 and 28|Number of subjects experiencing adverse events as a measure of safety, Number of subjects experiencing adverse events, Day -1 (baseline) to Day 28|pharmacokinetic profile of DS-8500a, Pharmacokinetic profile of DS-8500a in Japanese subjects with type 2 diabetes mellitus. i.e. Tmax, Cmax, AUC, t1/2, Day -1 (baseline) to Day 28|change in postprandial plasma glucose level, Change in postprandial plasma glucose level (2 hours after a meal) at Day 14 or 28 from Day -1, Day -1 (baseline) to Days 14 and 28
|
